ループス腎炎におけるマクロファージの役割

DOI DOI Web Site PubMed 参考文献40件
  • NOZAKI Yuji
    Department of Nephrology and Rheumatology, Kinki University Faculty of Medicine
  • NAGARE Yasuaki
    Department of Nephrology and Rheumatology, Kinki University Faculty of Medicine
  • HINO Shoichi
    Department of Nephrology and Rheumatology, Kinki University Faculty of Medicine
  • YANO Tomohiro
    Department of Nephrology and Rheumatology, Kinki University Faculty of Medicine
  • KISHIMOTO Kazuya
    Department of Nephrology and Rheumatology, Kinki University Faculty of Medicine
  • SHIMAZU Hideki
    Department of Nephrology and Rheumatology, Kinki University Faculty of Medicine
  • IKOMA Shinya
    Department of Nephrology and Rheumatology, Kinki University Faculty of Medicine
  • KINOSHITA Koji
    Department of Nephrology and Rheumatology, Kinki University Faculty of Medicine
  • FUNAUCHI Masanori
    Department of Nephrology and Rheumatology, Kinki University Faculty of Medicine

書誌事項

タイトル別名
  • Therapeutic strategy and significance of serum rheumatoid factor in patients with rheumatoid arthritis during infliximab treatment
  • The pathogenic role of macrophage in lupus nephritis

この論文をさがす

抄録

  To predict the response of patients with rheumatoid arthritis (RA) to infliximab, patient profile and laboratory findings were compared to determine whether there was any association with the clinical course of the disease, and the clinical significance of serum rheumatoid factor (RF) in the response to this treatment was considered. Sixty-two RA patients were treated with infliximab, 87.9% of whom were positive for RF. At baseline and 12 months after the start of treatment, RF titers were significantly lower in the low-CRP group (CRP at 12 months<0.3 mg/dl) compared with that in the high-CRP group (CRP at 12 months >1.5 mg/dl). Furthermore, at baseline and 12 months, RF titers were significantly lower in the good-CRP-response group (ΔCRP≥1.5 mg/d) compared with the poor-CRP-response group (ΔCRP≤0.3 mg/d). The percent changes in RF and CRP from baseline were correlated throughout the clinical course. The duration of disease in good-CRP-response group was shorter than that in poor-CRP-response group significantly. The rate of positivity for HLA-DR4 in good response group tends to be higher than that in poor-CRP-response group. We concluded that several factors, including disease duration, positivity for HLA-DR4, and the serum RF titer at baseline, might predict the patient response to infliximab.<br>

収録刊行物

参考文献 (40)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ